Insulin Potentiation Therapy (IPT) was invented in 1930 by a surgeon lieutenant of the Mexican military, Dr. Donato Pérez García, Sr. (1896-1971), as a remedy for chronic degenerative diseases. Insulin was first isolated from pancreatic tissue in Canada and used as a treatment for diabetes in early 1920’s, years later in Europe and in the USA, insulin was used to produce coma for short periods in patients with schizophrenia in an attempt to cure them. Among other uses, was to treat some forms of malnutrition.
So when Donato first learned about insulin’s discovery he formulated an experiment on himself, in search of a cure for his lifelong severe gastrointestinal problems.
In 1926, a non diabetic first injected himself with insulin, proving it was safe and efficient. After a series of treatments, his symptoms disappeared; he recovered appetite and full health again. The idea was that insulin helped his body tissues assimilate nutrients more efficiently and pondered that could just as well work with medication. Insulin could increase drug concentration potency in the central nervous system, given before various medications, changing the physical and chemical reactions that occurred in the blood, restoring balance and maintaining a state of good health. And it did. In 1930, Dr. Donato successfully treated a patient with neurosyphilis using the name of Cellular Therapy, later known as IPT.
Five years later he applied for U.S. patent of the treatment, where it was granted in 1938. He traveled along the United States demonstrating his medical protocol; at Harvard University, Saint Elizabeth’s Hospital in Washington, D.C., Naval Hospital in San Diego, California and Austin State Hospital in Texas where he treated patients. In Mexico City he opened up a clinic exclusively for IPT. In 1946 the first breast cancer patient was successfully treated. Many other chronic degenerative illnesses also responded to this innovative breakthrough.
Later on, his son, Dr. Donato Pérez GarcíaBellón (1930-2000) joined his father in the medical field, learning and perfecting the treatment. His clinical research was to measure chemical modifications produced in the blood after the administration of insulin, along with other chemical experiments and international publications that gave IPT full scientific ground. In his research, he concluded that cancer cells have as much as 8 times more insulin receptors in a cancer cell, than that of a normal cell. Together, father and son traveled to Canada, United States and Europe giving a series of conferences to medical societies.
After his father’s passing, Donato Pérez Bellón continued in his footsteps.
In 1974 he use the name “Donatian Therapy” to his adaptation of the treatment some modification of the treatment.
He allied with Dr. Steven G. Ayre, and the M.D. Anderson Cancer Center, together they promoted Insulin Potentiation Therapy in the United States, and began training physicians worldwide. Cases of polio, multiple sclerosis, gastric and duodenal ulcers, chronic infections, HIV/AIDS and other viral diseases where effectively treated with this protocol. But out of all, it was Cancer that he focused on, learning about improvements and adaptations as with the new drugs that were available.
Finally, the third generation of IPT came along with Dr. Donato Pérez García, who learned the protocol from his father. By December of 1982, he introduced the intravenous use of insulin to patients receiving the treatment. Later that month Dr. Donato implemented the first modification of the administration procedure and patients began with the new routine. By 1986 the name “Insulin Potentiation Therapy” was given by Dr. Ayre. Today the name of this therapy is “Insulin Potentiation Therapy Low Dose” or IPTLD ® (a registered trademark) and it is comprised of a combination of the best developed protocols. Thousands of patients treated by three Donato generations of medical doctors till this day.